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EditorialIs fatigue in primary biliary cirrhosis cured by transplantation?
Roman Zenouzi, Christina Weiler-Normann, Ansgar W. Lohse⇑University Medical Center Hamburg-Eppendorf, 1st Dept. of Medicine, Hamburg, GermanySee Article, pages 490–494The name primary biliary cirrhosis (PBC) was coined when the
disease was mostly diagnosed in its late cirrhotic stage [1]. Today,
PBC must be considered a historic misnomer, as the disease now-
adays presents usually many years or decades prior to the devel-
opment of cirrhosis, and with timely diagnosis and adequate
treatment, the majority of patients never reach the stage of cir-
rhosis [2–4]. It is considered an autoimmune disease character-
ized by non-suppurative destructive cholangitis, and it is thus
considered a disease of the small intra-hepatic bile ducts. How-
ever, there may be a second reason why PBC is a misnomer: prob-
ably the disease is not only conﬁned to the liver, but may have
extra-hepatic manifestations. In addition to the immune-medi-
ated inﬂammation in the liver, patients may suffer from a num-
ber of extra-hepatic manifestations as varied as Sicca-
syndrome, arthralgias and, most of all, fatigue.
Fatigue is a complex symptom characterized by the feeling of
exhaustion, lethargy, and discomfort. Fatigue affects 40–80% of
PBC patients [5,6]. Fatigue is not only common, for most patients
it also constitutes the primary clinical problem, as about 50% of
the patients affected describe fatigue as the most bothersome
symptom of their disease [7]. In addition to this enormous impact
on quality of life, new data suggest an inﬂuence on survival in
PBC, as well [8].
In order to meet this highly challenging problem in PBC, effec-
tive therapeutic strategies for patients affected by fatigue would
be highly desirable. However, to date there is no speciﬁc treat-
ment for fatigue in PBC [9]. Even though different drugs have
been tested in clinical trials, favorable effects have only been
shown for Modaﬁnil, such as decreased somnolence and night
sleep as well as increased energy levels [10,11], and for metho-
trexate [12], albeit only described in small case series without
adequate placebo controls. In addition to the limited effective-
ness, side-effects will limit therapeutic options frustrating both
patients and their treating physicians.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.The lack of effective therapeutic options for fatigue is
explained by our lack of understanding of the underlying patho-
physiology. What is the relation to the liver, and to the liver dis-
ease? Fatigue, but also other extra-hepatic symptoms in PBC
such as Sicca syndrome, calls into question that PBC is only a dis-
ease of the liver. None of these symptoms correlate in anymeasur-
able way with hepatic disease activity, nor do they correlate with
disease stage. In particular, no association could be found between
fatigue and the histological stage or degree of hepatocellular dys-
function [5,7,8,13]. It is therefore highly questionable that these
are simply extra-hepatic manifestations of a purely hepatic dis-
ease. They may, however, be different facets of a more systemic
disease. Understanding the pathophysiology of these disease
manifestations, and developing new treatment options out of this
understanding, is what PBC patients are probablymost hoping for.
Liver transplantation is not only an excellent, life-saving treat-
ment option for end-stage liver disease in PBC, it is also an exper-
iment into the pathophysiology of the disease, both hepatic and
extra-hepatic. If indeed fatigue is independent of liver disease,
transplantation is unlikely to affect fatigue. On the other hand,
if fatigue is cured by liver transplantation, this symptom is likely
to be a secondary manifestation of hepatic inﬂammation. This
seems to be a simple and important question to answer, but so
far it has never been studied systematically. In the current issue
of the Journal of Hepatology, Carbone et al. try to give an answer to
this question. In their prospective study, 49 patients with PBC
undergoing transplantation were included, however, only 31
could be included in the ﬁnal analysis. Two control cohorts were
identiﬁed, one healthy control group and one non-transplant PBC
group, both age- and sex-matched. Evaluation of the severity of
fatigue was done using the PBC-40, an established questionnaire
assessment tool for quality of life including fatigue in PBC [14].
Fatigue was assessed prior to transplantation as well as 6, 12,
and 24 months after the operation. Subgroup analyses were per-
formed regarding MELD and UKELD score.
The question, both clinically and scientiﬁcally, was straight-
forward: can liver transplantation cure fatigue in PBC? Disap-
pointingly, the answer to the question appears more complex
than one would have expected: fatigue is clearly improved in
this cohort by liver transplantation, but persists to a
considerable degree in many of the transplanted PBC patients.
In particular, in the transplanted PBC cohort, the number of
patients with moderate or severe fatigue was reduced from13 vol. 59 j 418–419
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89% before liver transplantation to less than 50% two years
afterwards; a signiﬁcant decrease, which was independent of
hepatic decompensation prior to transplantation. However, in
a relevant number of patients, signiﬁcant fatigue persisted after
liver transplantation and remained clearly higher than in the
healthy control group. These mixed results might be due to a
variety of factors: the group of patients studied was small,
and had a considerable drop-out rate, mainly due to death
(n = 12) or to the fact that patients withdrew from the study
after transplantation (n = 5), which might have lead to a certain
bias. Furthermore, advanced cirrhosis prior to transplantation
could have caused various degrees of minimal to manifest hepa-
tic encephalopathy. It may have been very difﬁcult to measure
fatigue in encephalopathic patients, and even though the
authors tried to control for that, minimal encephalopathy might
have escaped their assessment.
Most importantly, the authors failed to include an important
control group, which would have been patients transplanted for
other liver diseases. We know very little about fatigue following
liver transplantation, and the high fatigue scores in transplanted
PBC patients in this study could have been at least partly due to
factors unrelated to PBC, but related to liver transplantation. The
key question is, whether patients transplanted for PBC suffer
from signiﬁcantly more (and different kind of) fatigue than other
transplant recipients. Such a ﬁnding would strongly support the
concept of an extra-hepatic pathogenesis of fatigue in PBC.
Evidence for an extra-hepatic mechanism in the development
of fatigue in PBC has grown in the recent years and different
mechanisms for fatigue in PBC have been put forward. These
include autonomic nervous system dysfunction, progesterone
metabolites, psychological elements, mitochondrial dysfunction,
cytokines and adipokines as well as structural cerebral abnormal-
ities [9]. In this context, magnetic resonance imaging demon-
strated parenchymal changes in the globus pallidus as well as
white matter lesions in patients with PBC. Interestingly, these
abnormalities correlated to some extent with the severity of fati-
gue [15,16]. Data from a trans-cranial magnetic stimulation study
demonstrated CNS abnormalities in both non-transplanted and
transplanted patients [17]. This suggests persistent organic brain
injury as a possible factor in persistent fatigue in PBC.
Another possible mechanism of fatigue in PBC might be altera-
tionsof theneuroendocrineaxis. It canwell be that PBC is amoregen-
eralized small duct diseasemanifesting usually in the largest gland of
the body, the liver, but also in salivary glands and possibly in some
other ductular structures, including neuroendocrine organs.
Thus, we are left with half an answer: liver transplantation is
likely to improve fatigue in advanced PBC, but some fatigue is
likely to remain. This is a sufﬁciently encouraging piece of news
for PBC patients waiting for transplant. It is also sufﬁciently clear
to exclude transplantation as a therapeutic option for severe fati-
gue in the absence of advanced cirrhosis. However, it does not
sufﬁciently answer the key scientiﬁc question, if fatigue is an
extra-hepatic symptom of hepatic inﬂammation, or a manifesta-
tion of an extra-hepatic disease. In this respect, further studies of
the pathophysiology on this important issue are needed,
including assessment of structural CNS involvement as well asJournal of Hepatology 201the role of the neuroendocrine axis. Liver transplantation saves
the lives of patients with advanced PBC, and it may improve their
symptomatic fatigue, but only to some degree. The key for a cure
of fatigue in PBC probably lies outside of the liver.Conﬂict of interest
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